| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NSE - IMPACT BIOMEDICAL INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| Mi | DSS, Inc.: DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited | 299 | ACCESS Newswire | Transaction marks a significant milestone for DSS's investment in Impact Biomedical and establishes Zoar Limited as an NYSE American-listed pharmaceutical companyZoar Limited ordinary shares expected... ► Artikel lesen | |
| Mi | Zoar Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Di | IMPACT BIOMEDICAL INC. - 8-K, Current Report | - | SEC Filings | ||
| ZOAR Aktie jetzt für 0€ handeln | |||||
| Di | Zoar Ltd - 8-A12B, Registration of securities | - | SEC Filings | ||
| 09.11. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.11. | Impact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination | 604 | ACCESS Newswire | Special meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company... ► Artikel lesen | |
| 09.10. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | - | SEC Filings | ||
| 16.09. | Impact Biomedical files F-4 for business combination | 2 | Investing.com | ||
| 16.09. | Fusion mit Zoar Labs: Impact Biomedical reicht F-4-Antrag ein | 2 | Investing.com Deutsch | ||
| 16.09. | DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical's Proposed Business Combination with Zoar Limited | 2 | GlobeNewswire (USA) | ||
| 16.09. | Impact BioMedical, Inc.: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Limited | 557 | GlobeNewswire (Europe) | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the "Company" or "Impact") announced that a Form F-4 registration statement (the "Registration Statement") was filed with... ► Artikel lesen | |
| 15.09. | Impact Biomedical corrects merger exchange ratio, sets reverse stock split | 1 | Investing.com | ||
| 15.09. | Impact BioMedical, Inc. Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited | 313 | GlobeNewswire (Europe) | HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc (NYSE: IBO) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued... ► Artikel lesen | |
| 11.09. | Impact BioMedical beschließt Aktienzusammenlegung im Verhältnis 1 zu 12,62 | 1 | Investing.com Deutsch | ||
| 11.09. | Impact BioMedical approves 1-for-12.62 reverse stock split | 1 | Investing.com | ||
| 07.08. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.04. | Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans | 311 | GlobeNewswire (Europe) | HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 0,244 | -11,59 % | EyePoint auf UBS-Biopharma-Konferenz: DME-Hoffnungen federn Rückschlag bei feuchter AMD ab | ||
| ASSEMBLY BIOSCIENCES | 20,600 | +0,49 % | Assembly Bio schafft Wert - und Gilead wird vorgeführt ... | Satte 11 Milliarden US$ musste Gilead 2011 für den Hepatitis-C-Spezialisten Pharmasset schlussendlich auf den Tisch legen. Einige Jahre zuvor hätte der Pharmakonzern noch für 300 Millionen US$ zuschlagen... ► Artikel lesen | |
| AMARIN | 10,200 | -0,97 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,443 | +1,03 % | Filana Therapeutics: Jill Quigley Joins Board Ahead Of Simufilam Phase 2a Study | ||
| COMPASS PATHWAYS | 7,350 | +1,38 % | Compass Pathways, Johnson & Johnson und die FDA: Wer macht das Rennen um das erste Psychedelikum auf Rezept? | ||
| ALTIMMUNE | 1,268 | -9,04 % | Citizens reiterates Altimmune stock rating on expanding pemvidutide data | ||
| ACHIEVE LIFE SCIENCES | 5,350 | -2,73 % | Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications | SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 2,708 | -0,51 % | Corbus auf der Jefferies Global Healthcare Conference: Onkologie-Hoffnungsträger und Adipositas-Potenzial | ||
| IRONWOOD PHARMACEUTICALS | 4,320 | -0,92 % | IRONWOOD PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| GALECTIN THERAPEUTICS | 2,580 | +4,88 % | Galectin Therapeutics GAAP EPS of -$0.04 beats by $0.01 | ||
| DARE BIOSCIENCE | 0,450 | 0,00 % | Daré Bioscience expects DARE to PLAY dispensing to begin in November across 28 states | ||
| GRACE THERAPEUTICS | 1,720 | 0,00 % | Grace Therapeutics, Inc. - 8-K, Current Report | ||
| CITIUS PHARMACEUTICALS | 0,506 | -2,39 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| HYTN INNOVATIONS | 0,067 | 0,00 % | XFRA 85W0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILHYTN INNOVATIONS... ► Artikel lesen |